Tolerogenic pDCs in tumor infiltrates, on the other hand, are related to worse clinical outcomes because they resist tumor‐draining lymph nodes and surrounding solid tumors, as well as express high IDO.3, 153. The gene discussed is IDO1; the disease is neoplasm.